Physician profile
Leah Tehranchi
NPI 1427581289
$2,651.01
in general payments reported to CMS, 2019-2025
31 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.77 · 2020: $73.45 · 2021: $616 · 2022: $591 · 2023: $428 · 2024: $431 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $677.84 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $273.63 | 2020-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.50 | 2021-2025 | Stiolto Respimat |
| Abbott Laboratories | $204.68 | 2019-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $149.22 | 2023-2025 | Gemtesa |
| Novo Nordisk INC | $120.10 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $109.29 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $108.71 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $89.40 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.04 | 2021-2022 | |
| Astellas Pharma US INC | $72.22 | 2021 | |
| Exact Sciences Corporation | $60.35 | 2025 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $49.23 | 2024 | |
| Dexcom, INC. | $48.22 | 2022-2023 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $36.43 | 2024 | Watchman Flx |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.90 | 2022 | |
| Insmed, INC. | $31.98 | 2025 | Arikayce |
| Amgen INC. | $27.18 | 2021-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $23.34 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.16 | 2022 | |
| Si-Bone, INC. | $21.21 | 2025 | |
| Philips North America LLC | $19.77 | 2024 | (Ae4) Secretion Management |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.69 | 2023 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $15.85 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.70 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.40 | 2021 | |
| Verona Pharma, INC. | $14.20 | 2025 | Ohtuvayre |
| Nevro Corp. | $13.93 | 2023 | Senza |
| Teva Pharmaceuticals USA, INC. | $13.86 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.20 | 2023 | Eliquis |
| Neurocrine Biosciences, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Tehranchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.